Alpha-galactosidase

GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024

Retrieved on: 
Wednesday, February 14, 2024
Enzyme replacement therapy, Fabry disease, ICV, EMA, Intelligence, European, Glycolipid, ERT, Sanfilippo syndrome, Hunter syndrome, Death, MPS, Prevalence, ODD, Safety, Sanfilippo, IDS, Disorder, Patient, Hanmi Pharmaceutical, Fibrosis, Clinical trial, Knowledge, Kidney disease, Disease, Urine, Heart, Alpha-galactosidase, Phase, Male, Kidney, Glycogen storage disease, Brain, Orphan, Mouse, Pharmaceutical industry

YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.

Key Points: 
  • YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced on Feb. 14th that it has presented the development updates on its LSD (Lysosomal Storage Diseases) medicines at the WORLDSymposium 2024 held on Feb. 4th-9th, 2024 in San Diego, USA.
  • WorldSymposium 2024 is an international forum for Lysosomal Diseases experts to share and exchange insights for researching better treatment of the disease.
  • In 2012, GC Biopharma succeeded in developing the world's second treatment for Hunter syndrome, "Hunterase" solely using domestic technology.
  • GC Biopharma, together with Hanmi Pharmaceutical, is developing GC1134A/HM15421, a long-acting alpha-galactosidase that can be administered subcutaneously once a month to improve patient convenience.

Global Enzyme Replacement Therapy (ERT) Market Research Report 2023-2032 Featuring Key Players - Biomarin Pharmaceutical, Leadiant Biosciences, Pfizer, Sanofi, & AbbVie - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023
General Health, Pharmaceutical, Health, Elosulfase alfa, Alpha-mannosidosis, Research report, Hope, Prevalence, Enzyme replacement therapy, Fabry disease, Alpha-galactosidase, Liver, Ageing, FDA, Gaucher's disease, Ecosystem, Sebelipase alfa, DSM-IV codes, GAG, ERT, Enzyme, Glycogen storage disease type II, Pharmaceutical industry, Velmanase alfa, Medicine

The "Enzyme Replacement Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Enzyme Replacement Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.
  • In the forefront of medical advancement, the enzyme replacement therapy (ERT) market stands tall, offering vital treatment avenues for individuals grappling with chronic disorders arising from enzyme deficiencies.
  • The research report delves deep into the nuances of the ERT sector, highlighting market statistics, regional shares, and key players commanding significant market share.
  • The report also touches upon the market revenues, detailing contributions from key treatments like Sebelipase alfa, Elosulfase alfa, and more.

Intoleran Differentiates Gluten and Fructan Intolerances

Retrieved on: 
Thursday, October 6, 2022
Quality of life, Approximation error, Fructan, Lactose, Alpha-galactosidase, Diagnosis, Confusion, Sucrose, Triticale, Human, Immune system, Fructose, Degenerative disease, Food, Reflux, Galactose, Bloating, Flour, Dairy product

FORT LAUDERDALE, Fla., Oct. 6, 2022 /PRNewswire/ -- Everyone wants to say that they have a gluten intolerance. However, the dietary professionals at Intoleran have a solid argument that, more often than not, an intolerance to fructans is what is causing symptoms. It's the similarities in foods that contain gluten and fructans that makes the diagnosis difficult.

Key Points: 
  • Gluten is a protein that is found in various cereals, including wheat, barley, rye, and triticale.
  • "There's often a bit of confusion between gluten and fructans," explains Intoleran owner Harmen Treep, "Often eating grain products leads to an upset stomach or other digestional discomforts.
  • This is blamed on gluten, and if someone has celiac disease (meaning they're gluten intolerant), this is likely the culprit.
  • Intoleran products assist the digestive system by helping to properly digest food and, consequently, avoid many of the unpleasant side effects that come from food intolerances.

Fabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight

Retrieved on: 
Tuesday, October 4, 2022
ACE, GB3, Amicus, Hearing loss, Glycogen storage disease, Vertigo, Fabry disease, Lysosome, Disease, Prevalence, Man, Analgesic, Pain, Enzyme replacement therapy, ERT, Therapy, ADA, Overalls, Genetically modified bacteria, Headache, Sangamo Therapeutics, Patient, Sex linkage, United Kingdom, Tissue, Risk, Woman, FD, Population, Pharmaceutical industry, Lithium, Vaccine, Protalix BioTherapeutics, Fabry, Takeda, Alpha-galactosidase

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
  • The increasing prevalence of the disease, along with the promising emerging pipeline therapies with new mechanisms of action, will fuel the Fabry disease market during the forecast period.
  • In the European and Japanese Fabry disease treatment market, Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are currently the only approved therapies for Fabry disease patients.
  • To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

Fabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight

Retrieved on: 
Tuesday, October 4, 2022
ACE, GB3, Amicus, Hearing loss, Glycogen storage disease, Vertigo, Fabry disease, Lysosome, Disease, Prevalence, Man, Analgesic, Pain, Enzyme replacement therapy, ERT, Therapy, ADA, Overalls, Genetically modified bacteria, Headache, Sangamo Therapeutics, Patient, Sex linkage, United Kingdom, Tissue, Risk, Woman, FD, Population, Pharmaceutical industry, Lithium, Vaccine, Protalix BioTherapeutics, Fabry, Takeda, Alpha-galactosidase

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
  • The increasing prevalence of the disease, along with the promising emerging pipeline therapies with new mechanisms of action, will fuel the Fabry disease market during the forecast period.
  • In the European and Japanese Fabry disease treatment market, Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are currently the only approved therapies for Fabry disease patients.
  • To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

Y Combinator-backed Kiwi Biosciences Launches Novel Portable Enzymes To Make Food Painless For 15% of the Planet

Retrieved on: 
Wednesday, August 31, 2022
Enzyme, Garlic, Y Combinator, Lactase, Monash University, Mannitol, Harvard Innovation Labs, Alpha-galactosidase, Sorbitol, Harvard University, Medicine, Lactose, Biotechnology, FODMAP, IBS, Fructan, United Kingdom, Sugar, MPH, Gastrointestinal disease, Irritable bowel syndrome

CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- Kiwi Biosciences, the Y Combinator-funded biotech startup making food painless, launches the next generation FODZYME , a novel patent-pending enzyme supplement helping people enjoy their favorite foods, wherever they are.

Key Points: 
  • CAMBRIDGE, Mass., Aug. 31, 2022 /PRNewswire/ -- Kiwi Biosciences, the Y Combinator-funded biotech startup making food painless, launches the next generation FODZYME , a novel patent-pending enzyme supplement helping people enjoy their favorite foods, wherever they are.
  • These compounds, called FODMAPs, are particularly problematic for people with Irritable Bowel Syndrome (IBS), which affects 15% of the global population.
  • Backed by Y Combinator , Kiwi Biosciences is a human-centered biotech company creating elegant scientific solutions for extraordinary gut relief.
  • On a mission to make food painless, Kiwi Biosciences is working on a polyol-targeting formulation and advancing novel enzyme technologies to address all FODMAPs.

Kriya Appoints Pedro Huertas M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division

Retrieved on: 
Wednesday, August 17, 2022
Infectious Diseases, Hospitals, Genetics, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Multimedia, Ecosystem, Triangle Park (Quezon City), Silicon, Patient, Therapy, Degenerative disease, Twitter, Enzyme replacement therapy, Fabry disease, Ophthalmology, Conditional sentence, Genzyme, LinkedIn, Entrepreneurship, Disease, Pharmaceutical industry, Alpha-galactosidase, Kriyā, Pfizer

Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.

Key Points: 
  • Kriya Therapeutics, Inc. , a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, announced today that it has appointed Pedro Huertas, M.D., Ph.D., as Chief Medical Officer of its Rare Disease Division.
  • In his role, Dr. Huertas will be responsible for the direction and execution of the companys clinical, medical and scientific plans to advance its rare disease pipeline.
  • Prior to joining Kriya, Dr. Huertas served as Chief Medical Officer at Inozyme Pharma, Sentien Biotechnologies, and Eloxx Pharmaceuticals.
  • Earlier in his career, Dr. Huertas also held clinical and development roles at Pfizer, Shire, Amicus, and Genzyme Corp.
    Pedro brings a wealth of experience to Kriya as we continue to advance our rare disease gene therapy portfolio, said Shankar Ramaswamy, M.D., Co-Founder and Chief Executive Officer of Kriya.

Nuvalent Announces Leadership Promotions

Retrieved on: 
Wednesday, July 20, 2022
Chemistry, Duvelisib, View, Pharmaceutical Development and Technology, Biogen, Degenerative disease, U.S. Securities and Exchange Commission, Twitter, Hematology, Alpha-galactosidase, IND World's Fair Line, Research, HER2, Risk, Private Securities Litigation Reform Act, Government, Merck Serono, Brain, COVID-19, Multimedia, Cancer, Leadership, Quality assurance, Agios, Merck, Drug development, NSCLC, Company, Senior, Security (finance), Texas A&M University, LinkedIn, Patient, Nasdaq, ALK, Therapy, Neurology, Sanofi, Annual report, LLC, Columbia University, Harvard University, Management, Pharmaceutical industry, Architecture, Genzyme, Ivosidenib, Avelumab, Plerixafor, Infinity

CAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced two leadership team promotions. Darlene Noci, A.L.M. has been promoted to Chief Development Officer and will continue to oversee all global Product Development and Regulatory Affairs activities. Benjamin Lane, Ph.D. has been promoted to Senior Vice President, Technical Operations and will continue to oversee all Pharmaceutical Development and Quality Assurance activities.

Key Points: 
  • Benjamin Lane, Ph.D. promoted to Senior Vice President, Technical Operations
    CAMBRIDGE, Mass., July 20, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced two leadership team promotions.
  • Prior to joining Nuvalent, Ms. Noci held various regulatory, quality assurance and global development team leadership positions with increasing responsibility at X4 Pharmaceuticals, EMD Serono, Infinity, Sanofi, and Genzyme.
  • "These promotions reflect the significant contributions made by Darlene and Ben in establishing Nuvalent as a clinical-stage company with strong expertise in the development of novel oncology therapies," said James Porter, Ph.D., Chief Executive Officer at Nuvalent.
  • We routinely post information that may be important to investors on our website at www.nuvalent.com .Follow us on Twitter ( @nuvalent ) and LinkedIn .

Inozyme Pharma Appoints Kurt Gunter, M.D., as Chief Medical Officer

Retrieved on: 
Tuesday, June 7, 2022
Center for Biologics Evaluation and Research, KUUR, Hospira, University of Kansas School of Medicine, Company, Marketing, Gene, ERT, MBA, Food, Distinction, Johns Hopkins University, Annual report, Yale University, Alpha-galactosidase, Skeleton, ISCT, Biology, International Society, Security (finance), U.S. Securities and Exchange Commission, Enzyme replacement therapy, Private Securities Litigation Reform Act, Center, Nasdaq, Therapy, Cell, University, Fabry disease, FDA, Risk, Master of Science, Patient, ABCC6, GLOBE, Division, Technology, Shire (pharmaceutical company), Fabry, Research, Stanford University, ENPP1, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.

Key Points: 
  • BOSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the appointment of Kurt Gunter, M.D., as chief medical officer.
  • Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex, brings to Inozyme over 30 years of expertise in regulatory affairs, clinical development, and government relations.
  • It is a pleasure to welcome Kurt to the Inozyme team to lead Inozymes clinical development and regulatory strategy, said Axel Bolte, MSc, MBA, Inozymes co-founder, president, and chief executive officer.
  • Prior to Athenex, Dr. Gunter served as chief medical officer at Kuur Therapeutics (formerly Cell Medica), where he headed the medical affairs, clinical operations, and regulatory affairs departments.

Protalix BioTherapeutics Announces Poster Presentations at the 2022 Program: 7th Update on Fabry Disease

Retrieved on: 
Thursday, May 26, 2022
Program, A-DNA, Company, Fabry disease, PLX, Convention center, Adult, Efficacy, 2021 Essex County Council election, Deoxyribonuclease, Poster, Phase, TASE, Degenerative disease, Maritime Hotel, Investor, Pfizer, Alpha-galactosidase, FDA, Biomarker, Conference, Safety, Life, Pharmaceutical industry, Vaccine, Protalix BioTherapeutics, Patient, Fabry

CARMIEL, Israel, May 26, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSEAmerican:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that five poster presentations are scheduled to be available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities.

Key Points: 
  • CARMIEL, Israel, May 26, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSEAmerican:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx plant cell-based protein expression system, today announced that five poster presentations are scheduled to be available at the 2022 Program: 7th Update on Fabry Disease: Biomarkers, Progression and Treatment Opportunities.
  • Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx.
  • Protalix was the first company to gain U.S.Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system.
  • Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.